Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center

Abstract

Introduction The preservation of fertility is an integral part of care of children requiring gonadotoxic treatments for cancer or non‐malignant diseases. In France, the cryopreservation of ovarian tissue has been considered and has been offered as a clinical treatment since its inception. The aim of this study is to review 20 years of activity in fertility preservation by ovarian tissue cryopreservation (OTC) for children and the feasibility of oocyte isolation and cryopreservation from the ovarian tissue at a single center. Material and methods Retrospective study including patients aged 15 years or younger who underwent OTC, combined for some with oocyte cryopreservation of isolated oocytes, before a highly gonadotoxic treatment for malignant or non‐malignant disease was initiated. We describe the evolution of activities in our program for fertility preservation and patient characteristics at the time of OTC and follow up. Results From April 1998 to December 2018, 418 girls and adolescents younger than 15 years of age underwent OTC, representing 40.5% of all females who have had ovarian tissue cryopreserved at our center. In all, 313 patients had malignant diseases and 105 had benign conditions. Between November 2009 and July 2013, oocytes were isolated and also cryopreserved in 50 cases. The mean age of patients was 6.9 years (range 0.3‐15). The most frequent diagnoses in this cohort included neuroblastoma, acute leukemia and hemoglobinopathies; neuroblastoma being the most common diagnosis in very young patients. During follow up, three patients requested the use of their cryopreserved ovarian tissue. All had undergone ovarian tissue transplantation, one for puberty induction and the two others for restoring fertility. So far, no pregnancies have been achieved. Eighty‐four patients who had OTC died. Conclusions Ovarian tissue cryopreservation is the only available technique for preserving fertility of girls. To our knowledge this is the largest series of girls and adolescents younger than 15 years so far reported on procedures of OTC before highly gonadotoxic treatment in a single center.

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

“…For female patients, methods such as the cryopreservation of oocytes, embryos, or ovarian tissue may be offered [1,3,4,5,6]. The development of techniques for fertility preservation has rapidly evolved into a fruitful research field with a focus not only on patients of reproductive age, but also on children and adolescents [7], and programs for fertility preservation have been established in many countries and have reported a continuous increase in numbers of patients undergoing such procedures [8,9,10,11,12]. However, female fertility preservation options are challenging in several clinical situations, such as the case of pre-pubertal girls in whom mature oocyte cryopreservation is not feasible or when time constraints do not allow for hormonal stimulation aiming at mature egg retrieval in adult women.…”

Time to consider ovarian tissue cryopreservation for girls with Turner’s syndrome: an opinion paper

“…Three hundred and thirteen patients had malignant diseases, and 105 had benign conditions. Recently three patients had auto-transplantation but no pregnancy has been reported yet (Poirot et al, 2019). A systematic review evaluating FP options in women with TS included 67 studies.…”

Increasing of malignancy of breast cancer cells after cryopreservation: molecular detection and activation of angiogenesis after CAM-Xenotransplantation.

“…The bene ciaries include the prepubertal, adolescent, and young adults diagnosed with malignant diseases e.g. gastrointestinal carcinoma, leukemia and breast cancer [1,2]. Clinicians concern about the existence of disseminated cancer cells that are dormant in the ovaries before anti-cancer treatment [3].…”